Materials and Reagents

Materials

1.7 ml microfuge tube (Corning, Axygen^®, catalog number: MCT-175-C )
15 ml tube (Corning, catalog number: 430052 )
PCR tubes (Corning, Axygen^®, catalog number: PCR-0208-C )
Pipette tips

Bacterial strains

Electro-competent BL21-AI (Invitrogen, Genotype: F− ompT hsdS^B(rB−, mB−) gal dcm araB::T7RNAP-tetA, tet^r)
Electro-competent NEB5α (New England Biolabs)

Phage

WT T7 phage (laboratory collection. Available at ATCC, catalog number: BAA-1025-B2 )

Plasmids

pUC19 (Yanisch-Perron et al., 1985)
pWUR397 (Brouns et al., 2008. cas3 under T7 promoter, Kan^R)
pWUR400 (Brouns et al., 2008. cascade genes under T7 promoter, Str^R)
pWUR477 (Brouns et al., 2008. pACYCDuet-1 (Novagen) cloned with control spacers under T7 promoter, cam^R)

Enzymes

DpnI restriction enzyme (New England Biolabs, catalog number: R0176S )
T4 polynucleotide kinase (New England Biolabs, catalog number: M0201S ) used with T4 DNA ligase buffer (New England Biolabs, catalog number: M0202S )

Kits

Gel and PCR Clean-up Kit (MACHEREY-NAGEL, catalog number: 740609.50 )
KAPA HiFi PCR Kit (Roche Diagnostics, catalog number: 07958935001 )
Lamda Taq PCR Master mix (Lamda Biotech, catalog number: D123P-200 )
Quick Ligation Kit (New England Biolabs, catalog number: M2200L )

Reagents

Agar (BD, Difco^TM, catalog number: 214010 )
Ampicillin (Merck, catalog number: 171254 ; Stock 100 mg/ml in double-distilled water, filtered, -20 °C)
Chloramphenicol (Merck, catalog number: 220551 ; Stock 35 mg/ml in ethanol, filtered, -20 °C)
Isopropyl-β-D-thiogalactopyranoside (IPTG) (Bio-Lab, catalog number: 16242352 ; Stock 1 M in double-distilled water, filtered, -20 °C)
Kanamycin (Merck, catalog number: 420311 ; Stock 50 mg/ml in 50% glycerol and double-distilled water, filtered, -20 °C)
L-arabinose (Gold Bio, catalog number: A-300-1 ; Stock 20% in double-distilled water, filtered, RT)
LB (Luria-Bertani) medium (10 g/L tryptone, 5 g/L yeast extract and 5 g/L NaCl) (Acumedia)
Molecular biology water (Bio-Lab, catalog number: 232123 )
PEG 8000 (polyethylene glycol) (Promega, catalog number: V3011 ; Stock 50% in double-distilled water, filtered, RT)
Streptomycin (EMD Millipore, catalog number: 5711 ; Stock 50 mg/ml in double-distilled water, filtered, -20 °C)
TAE buffer (Bio-Lab, catalog number: 20502323 )

LB medium (see Recipes)
LB agar plates (see Recipes)
Soft agar (see Recipes)
TAE buffer (see Recipes)

Equipment

Cell density meter (OD₆₀₀ reader) (Amersham Biosciences, model: Ultrospec 10 )
Electroporation device (Bio-Rad Laboratories, model: MicroPulser^TM )
Gel electrophoresis apparatus (Cleaver Scientific, model: MultiSUB Choice )
Micro-centrifuge (Eppendorf, model: MiniSpin^® )
NanoDrop spectrophotometer (Thermo Fisher Scientific, Thermo Scientific^TM, model: NanoDrop^TM 2000c )
Pipettes
Shaker (for 50 ml tubes, at 37 °C) (Thermo Fisher Scientific, Thermo Scientific^TM, model: MaxQ^TM 2000 )
Thermal Cycler (Bio-Rad Laboratories, model: C1000 Touch^TM )
Thermoblock (Labnet International, model: AccuBlock^TM Digital Dry Baths )

Procedure

Plasmid construction
1. Construction of pGeneX
  This plasmid encodes DNA homologous to the upstream and downstream sequences of the target genetic locus. These DNA will recombine with the desired locus thus generating the desired recombinant phages (Figure 1).
2. Construction of pAnti-GeneX
  This plasmid encodes specific spacers that will serve to target the unmodified phage, thus enabling selection of the modified phage.
  1. Perform a PCR amplification reaction with pWUR477 plasmid as a template using primers with 5’ overhangs that form a new spacer upon ligation. See Figure 2 below.
    
    Note: Minimum reaction volume of 30 µl.
    
    Figure 2. Schematics of the pAnti-GeneX construct. A. An example of a primer design yielding a spacer to target gene X. The targeted DNA is in pink. This protospacer is a 33 bp sequence in the gene of interest and is preceded by an AA, yielding a functional protospacer-adjacent motif (PAM). The forward and reverse primers encode annealing sequences to the pWUR477 template, and 5’ overhangs which together form the desired spacer sequence. B. PCR amplification with the forward and reverse primers on the pWUR477 plasmid and self-ligation to construct the pAnti-GeneX plasmid. Grey rectangles represent repeat sequences, pink represents the new spacer, orange represents spacer 2 and red represents spacer 3, and black represents the plasmid backbone.
  2. Add 1 µl of restriction enzyme DpnI directly to the PCR mixture to eliminate residues of the pWUR477.
  3. Incubate for 1 h at 37 °C.
  4. Isolate DNA product according to size using gel electrophoresis.
  5. Purify the product using Gel and PCR Clean-up kit according to the manufacturer’s instructions. Elute in 20 µl.
  6. Phosphorylate the purified DNA:
    1. Incubate the purified DNA at 70 °C for 5 min.
    2. Cool on ice for 5 min.
    3. Add to the 20 µl purified DNA:
      3 µl T4 DNA ligase buffer.
      1 µl T4 polynucleotide kinase.
      3 µl PEG-800 (50%).
      3 µl molecular biology water.
    4. Incubate for 30 min at 37 °C.
    Note: DNA oligos could also be synthesized with a 5’-phosphate. In such cases, step A2f should be skipped.
  7. Purify the product using Gel and PCR Clean-up kit the according to the manufacturer’s instructions. Elute in 20 µl.
  8. Self-ligate the phosphorylated DNA:
    1. Add to 10 µl phosphorylated DNA:
      10 µl Quick ligation buffer
      1 µl Quick ligase enzyme
    2. Incubate for 15 min at 25 °C.
  9. Purify the product using Gel and PCR Clean-up kit according to the manufacturer’s instructions. Elute in 20 µl.
Preparation of recombinant T7 lysate
1. Transform the pGeneX and the pUC19 plasmid (lacking the homologous sequences) as a control into NEB5α cells.
2. Inoculate one colony of each transformant into 3 ml LB supplemented with 100 µg/ml ampicillin and shake at 37 °C, overnight.
3. Dilute overnight cultures 1:100 into 6 ml fresh LB, supplemented with 100 µg/ml ampicillin.
4. Shake at 37 °C to an OD₆₀₀ ~1.
5. Infect 5 ml of each culture with WT T7 phage at an MOI of ~0.1 (10⁷-10⁸ PFU). Leave the remaining 1 ml culture as an uninfected control.
6. Shake the infected bacteria at 37 °C until lysis occurs (usually 2 h).
  Note: Lysis can be recognized by ‘clear’ culture, strings of cell debris or a translucent appearance.
Select T7 engineered phages
1. Transform pWUR397, pWUR400 and targeting plasmid (pAnti-GeneX) or a control plasmid (pWUR477), into BL21-AI cells.
2. Inoculate one colony of each transformant into 3 ml LB supplemented with 50 µg/ml streptomycin, 50 µg/ml kanamycin and 35 µg/ml chloramphenicol and shake at 37 °C, overnight.
3. Prepare at least 4 LB agar plates (see Recipes) supplemented with 50 µg/ml streptomycin, 50 µg/ml kanamycin and 35 µg/ml chloramphenicol.
4. Dilute overnight cultures 1:100 into 5 ml fresh LB supplemented with the appropriate antibiotics.
5. Shake at 37 °C (without inducers) until OD₆₀₀ ~1.
6. Add 0.2% L-arabinose and 0.1 mM IPTG (final concentrations) to the cultures.
7. Shake at 37 °C for an additional hour.
8. Pre-warm soft agar (0.7% agar, see Recipes) to a liquid phase. Add 0.2% L-arabinose and 0.1 mM IPTG to the agar and keep at 50 °C.
9. Pre-warm LB agar plates with the antibiotics prepared in step C3 for at least 1 h at 37 °C.
10. For every combination of phage and bacteria (see Table 1), mix in a 15 ml tube:
  100 µl bacteria (from step C7).
  10 µl phage lysates prepared in ‘Preparation of recombinant T7 lysate’.
  3.5 ml of the pre-warmed soft agar (0.7%) with inducers.
  
  Table 1. Combinations of phage with bacteria. All four different combinations: targeting/non-targeting bacteria with recombinant/non-recombinant lysates.
11. Vortex briefly and IMMEDIATELY pour onto the pre-warmed plates. Gently tilt and rotate plate to spread top agar evenly.
12. Allow the plates to cool for 5 min, invert, and incubate overnight at RT or for 4-6 h at 37 °C (until plaques are visible).
Isolation and validation
1. Inoculate one colony of targeting bacteria (BL21-AI/pWUR397, pWUR400, pAnti-GeneX) into 3 ml LB supplemented with 50 µg/ml streptomycin, 50 µg/ml kanamycin and 35 µg/ml chloramphenicol.
2. Shake at 37 °C overnight.
3. Dilute plaques larger than 0.4 cm into 100 µl LB.
  Note: Small plaques are expected even on the control plates. Desired plaques (i.e., ones that have the desired deletion mutation) should appear 3-5 times larger than the background plaques.
4. Perform a PCR amplification reaction on the diluted plaque for validation: Use primers upstream and downstream to geneX. Determine gene deletion according to PCR product size. Use wild-type T7 as a template for positive control. See Figure 3.
  Note: Deletion of a fragment encoding the corresponding protospacer can result in isolated phages that do not encode the desired deletion (by escaping the CRISPR-Cas targeting).
  
  Figure 3. Illustration for PCR validation. Forward and reverse primers anneal upstream and downstream to geneX (green). PCR amplification on the edited phage results in a smaller DNA product. PCR amplification of the WT phage or phage with deletion of a fragment encoding the corresponding protospacer results in a full length DNA product. Black square represents gel electrophoresis, white bands represent DNA products.
5. Pre-warm soft agar (0.7% agar) to a liquid phase. Add 0.2% L-arabinose and 0.1 mM IPTG (final concentrations) to the agar and keep at 50 °C.
6. Pre-warm LB agar plates for at least 1 h at 37 °C. One plate for every modified phage.
7. Streak positive deleted phages on the pre-warmed LB agar plate.
8. For each modified phage, mix in a 15 ml tube:
  200 µl of the targeting bacteria
  3 ml of the pre-warmed soft agar with the inducers
9. Gently pour the soft-agar with the bacteria on the streaked plates (from step D6).
  Note: Pour the soft-agar with the bacteria on the lower concentration area and let the fluid spread to the high concentration end.
10. Allow the plates to cool for 5 min, invert, and incubate overnight at RT or for 4-6 h at 37 °C (until plaques are visible).
11. Pick one plaque from each plate and repeat steps D3-D9, 3 times.
12. Perform a PCR amplification on an isolated phage and validate desired sequence with DNA sequencing.
13. Dilute 1:50 targeting bacteria into 5 ml LB supplemented with 50 µg/ml streptomycin, 50 µg/ml kanamycin and 35 µg/ml chloramphenicol, 0.2% L-arabinose and 0.1 mM IPTG.
14. Shake at 37 °C to an OD₆₀₀ ~0.5.
15. Infect the culture with 10 µl of the validated engineered phage.
16. Shake the infected bacteria at 37 °C until lysis occurs (usually 2 h).

Data analysis

A flow chart of the protocol is shown in Figure 4. An overview of the procedures for isolating desired recombinant bacteriophage and percentages of engineered cells can be found in the original paper (Kiro et al., 2014).

Figure 4. Flow chart of the protocol

Recipes

LB medium

Measure 20 g LB (Luria-Bertani) medium powder and fill up to 1 L with deionized water
Autoclave solution and cool down
Store at RT

LB agar plates

Measure 7.5 g agar and add sterile LB medium up to 500 ml
Autoclave the solution, cool down and add antibiotics
Pour into Petri dishes
Wait until the agar solidifies
Store at 4 °C

Soft agar

Measure 1.75 g agar and add sterile LB medium up to 250 ml
Autoclave the solution and cool down
Store at RT

TAE buffer

Pour 200 ml of TAE buffer (stock) and add deionized water up to 10 L
Mix thoroughly
Store at RT

Acknowledgments

The research leading to these results was funded by the European Research Council under the European Community’s Seventh Framework Programme (FP7/207-2013)/ERC grant agreement No. 336079 (EcCRISPR). The protocol described here is adapted from (Kiro et al., 2014).

References

Bikard, D., Euler, C. W., Jiang, W., Nussenzweig, P. M., Goldberg, G. W., Duportet, X., Fischetti, V. A. and Marraffini, L. A. (2014). Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat Biotechnol 32(11): 1146-1150.
Box, A. M., McGuffie, M. J., O'Hara, B. J. and Seed, K. D. (2015). Functional analysis of bacteriophage immunity through a type I-E CRISPR-Cas system in Vibrio cholerae and its application in bacteriophage genome engineering. J Bacteriol 198(3): 578-590.
Brouns, S. J., Jore, M. M., Lundgren, M., Westra, E. R., Slijkhuis, R. J., Snijders, A. P., Dickman, M. J., Makarova, K. S., Koonin, E. V. and van der Oost, J. (2008). Small CRISPR RNAs guide antiviral defense in prokaryotes. Science 321(5891): 960-964.
Citorik, R. J., Mimee, M. and Lu, T. K. (2014). Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nat Biotechnol 32(11): 1141-1145.
Edgar, R., Friedman, N., Molshanski-Mor, S. and Qimron, U. (2012). Reversing bacterial resistance to antibiotics by phage-mediated delivery of dominant sensitive genes. Appl Environ Microbiol 78(3): 744-751.
Harper, D. R. and Enright, M. C. (2011). Bacteriophages for the treatment of Pseudomonas aeruginosa infections. J Appl Microbiol 111(1): 1-7.
Kiro, R., Shitrit, D. and Qimron, U. (2014). Efficient engineering of a bacteriophage genome using the type I-E CRISPR-Cas system. RNA Biol 11(1): 42-44.
Lemay, M. L., Tremblay, D. M. and Moineau, S. (2017). Genome engineering of virulent lactococcal phages using CRISPR-Cas9. ACS Synth Biol.
Marinelli, L. J., Piuri, M., Swigonova, Z., Balachandran, A., Oldfield, L. M., van Kessel, J. C. and Hatfull, G. F. (2008). BRED: a simple and powerful tool for constructing mutant and recombinant bacteriophage genomes. PLoS One 3(12): e3957.
Martel, B. and Moineau, S. (2014). CRISPR-Cas: an efficient tool for genome engineering of virulent bacteriophages. Nucleic Acids Res 42(14): 9504-9513.
Merril, C. R., Scholl, D. and Adhya, S. L. (2003). The prospect for bacteriophage therapy in Western medicine. Nat Rev Drug Discov 2(6): 489-497.
Pires, D. P., Cleto, S., Sillankorva, S., Azeredo, J. and Lu, T. K. (2016). Genetically engineered phages: a review of advances over the last decade. Microbiol Mol Biol Rev 80(3): 523-543.
Selick, H. E., Kreuzer, K. N. and Alberts, B. M. (1988). The bacteriophage T4 insertion/substitution vector system. A method for introducing site-specific mutations into the virus chromosome. J Biol Chem 263(23): 11336-11347.
Suttle, C. A. (2007). Marine viruses--major players in the global ecosystem. Nat Rev Microbiol 5(10): 801-812.
Weber-Dabrowska, B. Mulczyk, M. and Górski, A. (2001). Bacteriophage therapy for infections in cancer patients. Clin Appl Immunol Rev 1(3-4): 131-134.
Yanisch-Perron, C., Vieira, J. and Messing, J. (1985). Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. Gene 33(1): 103-119.
Yosef, I., Kiro, R., Molshanski-Mor, S., Edgar, R. and Qimron, U. (2014). Different approaches for using bacteriophages against antibiotic-resistant bacteria. Bacteriophage 4(1): e28491.
Yosef, I., Manor, M., Kiro, R. and Qimron, U. (2015). Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria. Proc Natl Acad Sci U S A 112(23): 7267-7272.